ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
Static and Dynamic
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Kinetic modelling of [⁶⁸Ga]Ga-FAPI-46 PET in pancreaticobiliary lesions: distinguishing cancer from pancreatitis.European journal of nuclear medicine and molecular imaging · 2026Article
- The impact of scan time on dynamic [Formula: see text]-FAPI-04 total-body PET parametric imaging generated by deep learning models.EJNMMI physics · 2026Article
- Parametric mapping of dynamicCancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Article
- Digital Biopsy and Network Analysis of Dynamic [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Image analysis:Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Stromal Cells in Early Inflammation-Related Pancreatic Carcinogenesis-Biology and Its Potential Role in Therapeutic Targeting.Cancers · 2025Review
- Advancements in early detection of pancreatic cancer: the role of artificial intelligence and novel imaging techniques.Abdominal radiology (New York) · 2025Review
- Clinical Utility ofMedComm · 2025Article
- Dynamic FDG PET/CT imaging: quantitative assessment, advantages and application in the diagnosis of malignant solid tumors.Frontiers in oncology · 2025Review
- Systematic review and meta-analysis of the prognostic role of fibroblast-activation protein in gastrointestinal cancers.Journal of gastrointestinal oncology · 2024Article
- Prospective Comparison of [Molecular imaging and biology · 2024Article
- Pancreatic Cancer: A Review of Risk Factors.Life (Basel, Switzerland) · 2024Review
- The earliest optimal timing for total-bodyEuropean radiology · 2024Article
- Diagnostic Potential of Supplemental Static and DynamicJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Current considerations on intraductal papillary neoplasms of the bile duct and pancreatic duct.World journal of gastroenterology · 2024Article
- Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging.Biomedicines · 2024Review
- Immunohistochemical FAP Expression ReflectsJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- From FDG and beyond: the evolving potential of nuclear medicine.Annals of nuclear medicine · 2023Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) may arise from intraductal papillary mucinous neoplasms (IPMN) with malignant transformation, but a significant portion of IPMN remains to show benign behavior. Therefore, it is important to differentiate between benign IPMN and IPMN lesions undergoing malignant transformation. However, nonoperative differentiation by ultrasound, CT, MRI, and carbohydrate antigen 19-9 (CA19-9) is still unsatisfactory. Here, we assessed the clinical feasibility of additional assessment of malignancy by PET using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.